Moolec Science SA revenue

Moolec Science SA's revenue was $334m in fiscal 2025, down 28.5% on the year before.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Moolec Science SA: revenue history, annual
Fiscal year	2023Jun 2023	2024Jun 2024	2025Jun 2025
Revenue	421	466	334
Growth on the year before	—	+10.8%	−28.5%
Gross profit	185	187	130
Gross margin	44.1%	40.1%	39.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Moolec Science SA	$334m	-28.5%	—
Iovance Biotherapeutics, Inc.	$325m	34.5%	—
Arvinas, Inc.	$317m	-15.0%	26.1%
Adaptive Biotechnologies Corp	$308m	50.1%	17.6%
Vericel Corp	$306m	23.0%	19.8%
Vir Biotechnology, Inc.	$303m	1495.9%	-14.8%

Compare with peers

Head to head: IOVA vs MLEC ARVN vs MLEC ADPT vs MLEC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Moolec Science SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Moolec Science SA.